Comparative characteristics of B-type natriuretic peptide expression in the left atrial myocardium in various phenotypes of chronic heart failure and its relationship with plasma NT-proBNP level

Background. Chronic heart failure (CHF) remains a leading cause of hospitalizations and mortality. Measuring blood NT-proBNP concentration is recognized as the “gold standard” for CHF diagnosis. Normally, the atria are considered the primary source of atrial natriuretic peptide (ANP); however, their true contribution to systemic hyperpeptidemia due to B-type natriuretic peptide (BNP) during the progression of various CHF phenotypes and the reduction of left ventricular ejection fraction (LVEF) remains insufficiently studied. Objective. To compare B-type natriuretic peptide (BNP) expression in the left atrial (LA) myocardium across different CHF phenotypes and evaluate its association with plasma level of NT-proBNP. Materials and Methods. In a prospective clinical and morphological study, 75 patients with coronary artery disease after elective coronary artery bypass grafting were examined: comparison group (without clinically manifest CHF, n = 17), CHF with preserved EF (≥ 50 %, n = 20), and a cohort of CHF with reduced/mildly reduced EF (< 50 %, n = 38). BNP expression in LA appendage biopsies was assessed immunohistochemically (percentage of positive cells, H-score). Plasma NT-proBNP levels were determined by ELISA. Results. Plasma NT-proBNP concentrations increased proportionally to the decrease in LVEF: 296.6 pg/mL in the comparison group, 678.8 pg/mL at EF ≥ 50 %, and 1033.2 pg/mL at EF < 50 % (p < 0.001). Meanwhile, tissue BNP expression in the LA remained stable: the percentage of positive cells was 41.5–42.7 %, and the H-score was 64.4–74.3 points (p = 0.139). No significant correlation was found between the LA tissue H-score and plasma NT-proBNP (r = –0.084; p = 0.455). Conclusion. BNP expression in the LA myocardium reaches a functional “atrial plateau” already in coronary artery disease patients without clinical signs of CHF. The lack of increased BNP production in the atria despite the decrease in LVEF indirectly indicates that the ventricular myocardium is the dominant driver of systemic hyperpeptidemia in the manifest stages of the disease.

Authors

Institutions

Publication Details

Journal
Translational Medicine
Published
2026-11-16
DOI
https://doi.org/10.18705/2311-4495-2026-13-5-422-434
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative characteristics of B-type natriuretic peptide expression in the left atrial myocardium in various phenotypes of chronic heart failure and its relationship with plasma NT-proBNP level

Мустафина Ирина Аликовна, Naufal Sh. Zagidullin, Margarita R. Plotnikova, Vlas S. Shchekin et al.
Translational Medicine
Heart Failure Treatment and Management
article

Comparative characteristics of B-type natriuretic peptide expression in the left atrial myocardium in various phenotypes of chronic heart failure and its relationship with plasma NT-proBNP level

Мустафина Ирина Аликовна, Naufal Sh. Zagidullin, Margarita R. Plotnikova, Vlas S. Shchekin, Терегулов Ильдар Ильшатович, Власова Ангелина Олеговна, Валинуров Тимур Ирекович
article en

Abstract

Background. Chronic heart failure (CHF) remains a leading cause of hospitalizations and mortality. Measuring blood NT-proBNP concentration is recognized as the “gold standard” for CHF diagnosis. Normally, the atria are considered the primary source of atrial natriuretic peptide (ANP); however, their true contribution to systemic hyperpeptidemia due to B-type natriuretic peptide (BNP) during the progression of various CHF phenotypes and the reduction of left ventricular ejection fraction (LVEF) remains insufficiently studied. Objective. To compare B-type natriuretic peptide (BNP) expression in the left atrial (LA) myocardium across different CHF phenotypes and evaluate its association with plasma level of NT-proBNP. Materials and Methods. In a prospective clinical and morphological study, 75 patients with coronary artery disease after elective coronary artery bypass grafting were examined: comparison group (without clinically manifest CHF, n = 17), CHF with preserved EF (≥ 50 %, n = 20), and a cohort of CHF with reduced/mildly reduced EF (< 50 %, n = 38). BNP expression in LA appendage biopsies was assessed immunohistochemically (percentage of positive cells, H-score). Plasma NT-proBNP levels were determined by ELISA. Results. Plasma NT-proBNP concentrations increased proportionally to the decrease in LVEF: 296.6 pg/mL in the comparison group, 678.8 pg/mL at EF ≥ 50 %, and 1033.2 pg/mL at EF < 50 % (p < 0.001). Meanwhile, tissue BNP expression in the LA remained stable: the percentage of positive cells was 41.5–42.7 %, and the H-score was 64.4–74.3 points (p = 0.139). No significant correlation was found between the LA tissue H-score and plasma NT-proBNP (r = –0.084; p = 0.455). Conclusion. BNP expression in the LA myocardium reaches a functional “atrial plateau” already in coronary artery disease patients without clinical signs of CHF. The lack of increased BNP production in the atria despite the decrease in LVEF indirectly indicates that the ventricular myocardium is the dominant driver of systemic hyperpeptidemia in the manifest stages of the disease.

Translational MedicineVol. 13(5)
Bashkir State Medical University (RU)
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon